A computer screen with the SDM website open.

WFH SDM Tool celebrates one year of enhancing hemophilia care

The WFH Shared Decision Making (SDM) Tool has just marked its first anniversary as a transformative resource for people with hemophilia (PWH) A and B and their caregivers. Since its launch on August 1, 2023, the WFH SDM Tool has facilitated informed decision-making by providing personalized treatment insights and fostering collaboration between PWH and their healthcare teams. Available in multiple languages, the tool continues to grow and adapt to user needs and available evidence.

Also available in: Français Español

The WFH Shared Decision Making (SDM) Tool is a web-based interactive decision-support system designed to assist PWH and their caregivers who are considering changes in their current treatment regimen. Users are guided through a series of value-based questions they can consider. They are also provided with evidence-based educational content on five prophylactic treatment classes for hemophilia. This living tool is updated twice per calendar year, ensuring that users always have access to the most current information.

In early 2024, the WFH conducted a three-part webinar series focused on shared decision-making for hemophilia. These sessions covered the assessment of risks and benefits for different treatment classes, and highlighted the advantages of using the WFH SDM Tool for both PWH and healthcare providers. Additional training sessions were also held regionally, including an in-person training held in Bogota, Colombia, and sessions at the WFH 2024 World Congress—further emphasizing the tool’s value and application.

Looking ahead, a pilot study is in development to assess the effectiveness of the WFH SDM Tool in real-world settings. This study aims to provide insights into how the WFH SDM Tool supports collaborative decision-making among key stakeholders, and its broader impact on the hemophilia community. 

Currently available in English, French, Spanish, Japanese, German and Dutch, with additional translations planned for the future, the WFH SDM Tool is intended to be accessible to a global audience. From August 1, 2023, to August1, 2024, the tool attracted over 8,500 unique visitors from 138 countries, reflecting its growing influence and reach.  

WFH SDM Tool users by country

As we celebrate this milestone, the WFH invites everyone to explore the potential of shared decision-making in enhancing hemophilia care.

To find out more about shared decision-making for hemophilia treatments, visit the WFH eLearning platform. To access the WFH SDM Tool, click here for a web-based version, or here for a PDF version.

The WFH thanks our Corporate Partners BioMarin Pharmaceutical Inc., CSL Behring, F. Hoffmann-La Roche, Novo Nordisk, Pfizer, Sanofi and Sobi.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.